fashion -WSS

fashion

author：entertainment 2025-09-27 09:55:03 - browse：9722

Fiona Marshall, president of the Novartis research hub in Cambridge, Mass., speaks Thursday during the STAT Future Summit. STAT

Swiss drugmaker Novartis’ research and development hub has a new name — and a new guiding strategy.

The hub, which is headquartered in Cambridge, Mass., and for years has been known as Novartis Institutes for BioMedical Research, or NIBR, will soon simply be known as Novartis Biomedical Research.

But that’s not the only thing that’s changing, Fiona Marshall, the hub’s president, told a virtual audience Thursday during the 2023 STAT Future Summit. The new name reflects a larger shift by the pharma giant to retool its research strategy — from one driven by the pure pursuit of scientific discovery to a tighter focus on projects likely to yield commercially successful drugs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Emergency medicine has repudiated 'excited delirium.' Now what?

WSS

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

What to know about Saharan dust affecting the US and how it can affect health

Russian special forces kill a gunman who broke into a private house near Moscow

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Readout Newsletter: XBI biotech index, Akero Therapeutics

New rules on organ donation and transplantation 'will bring chaos'

entertainment

fashion

knowledge

New air purifier tech could be key to improving indoor air quality

Russian special forces kill a gunman who broke into a private house near Moscow

United colonoscopy coverage change 'may cost lives,' doctors say

Organ transplantation is at a crossroads. Major reform is needed

The cancer drug shortage isn’t new — and neither are the solutions

Meta's Zuckerberg and Chan on track to put $50 billion into science

Alkermes shareholders re

Testing for cancer recurrence creates a new limbo for patients

Bright Health sells Medicare Advantage business to Molina

7 of the most gruesome medical devices in history

focus

Our daughter's deadly disease: trisomy 18. We wanted to protect her

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

The FDA weighs the risks of candy

How artificial intelligence is being used to detect, treat cancer

What to know about Saharan dust affecting the US and how it can affect health

First Opinion Podcast: How to protect health care in times of war

hotspot

entertainment

Wikipedia

hotspot